Bozeman, MT (April 29, 2008) – Golden Helix announced today that the company’s CEO, Dr. Christophe Lambert, has been chosen to co-chair the Copy Number Variation Data Analysis Team within the Genome-Wide Association Working Group, part of the Microarray Quality Control (MAQC) Consortium led by the National Center for Toxicological Research (NCTR) of the FDA. Lambert will join co-chair Dr. Francesca Demichelis of the Institute for Computational Biomedicine at Weill Cornell Medical College.
Lambert presented promising genome-wide copy number association findings at the most recent MAQC meeting, based on data from the Wellcome Trust Case Control Consortium.
“In the future, diagnostics and prognostics will require the incorporation of many forms of patient assay information. The inclusion of copy number variation is a logical progression to build on the information content of gene expression and genotype information,” affirmed Lambert. “We anticipate that best practices will emerge to assist companies in bringing more effective diagnostics to market. It will also help the FDA in making better decisions as more IVDMIA’s (In Vitro Diagnostic Multivariate Index Assays) are submitted for regulatory approval.”
According to Lambert, the CNV Data Analysis Team, which now has over 50 members, has the following charge:
To identify the sources of variation in results of analysis of copy number data on whole genome microarrays with respect to the goals of:
About Golden Helix, Inc.
Founded in 1998, Golden Helix has become the global leader in SNP, copy number, and genetic association software. The company's products are used by hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations, and have been cited in over 100 peer reviewed publications that detail ground-breaking research uncovering the genetic and environmental basis of disease. Golden Helix is committed to Accelerating the Quest for Significance. For more information, visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.